Literature DB >> 11949985

Risk factors for elevated HIV incidence rates among female injection drug users in Vancouver.

Patricia M Spittal1, Kevin J P Craib, Evan Wood, Nancy Laliberté, Kathy Li, Mark W Tyndall, Michael V O'Shaughnessy, Martin T Schechter.   

Abstract

BACKGROUND: In 1997, we found a higher prevalence of HIV among female than among male injection drug users in Vancouver. Factors associated with HIV incidence among women in this setting were unknown. In the present study, we sought to compare HIV incidence rates among male and female injection drug users in Vancouver and to compare factors associated with HIV seroconversion.
METHODS: This analysis was based on 939 participants recruited between May 1996 and December 2000 who were seronegative at enrolment with at least one follow-up visit completed, and who were studied prospectively until March 2001. Incidence rates were calculated using the Kaplan-Meier method. The Cox proportional hazards regression model was used to identify independent predictors of time to HIV seroconversion.
RESULTS: As of March 2001, seroconversion had occurred in 110 of 939 participants (64 men, 46 women), yielding a cumulative incidence rate of HIV at 48 months of 13.4% (95% confidence interval [CI] 11.0%-15.8%). Incidence was higher among women than among men (16.6% v. 11.7%, p = 0.074). Multivariate analysis of the female participants' practices revealed injecting cocaine once or more per day compared with injecting less than once per day (adjusted relative risk [RR] 2.6, 95% CI 1.4-4.8), requiring help injecting compared with not requiring such assistance (adjusted RR 2.1, 95% CI 1.1-3.8), having unsafe sex with a regular partner compared with not having unsafe sex with a regular partner (adjusted RR 2.9, 95% CI 0.9-9.5) and having an HIV-positive sex partner compared with not having an HIV-positive sex partner (adjusted RR 2.7, 95% CI 1.0-7.7) to be independent predictors of time to HIV seroconversion. Among male participants, injecting cocaine once or more per day compared with injecting less than once per day (adjusted RR 3.3, 95% CI 1.9-5.6), self-reporting identification as an Aboriginal compared with not self-reporting identification as an Aboriginal (adjusted RR 2.5, 95% CI 1.4-4.2) and borrowing needles compared with not borrowing needles (adjusted RR 2.0, 95% CI 1.1-3.4) were independent predictors of HIV infection.
INTERPRETATION: HIV incidence rates among female injection drug users in Vancouver are about 40% higher than those of male injection drug users. Different risk factors for seroconversion for women as opposed to men suggest that sex-specific prevention initiatives are urgently required.

Entities:  

Mesh:

Year:  2002        PMID: 11949985      PMCID: PMC100922     

Source DB:  PubMed          Journal:  CMAJ        ISSN: 0820-3946            Impact factor:   8.262


  25 in total

1.  Injection drug use and despair through the lens of gender.

Authors:  P M Spittal; M T Schechter
Journal:  CMAJ       Date:  2001-03-20       Impact factor: 8.262

2.  Gendered power dynamics and HIV risk in drug-using sexual relationships.

Authors:  R MacRae; E Aalto
Journal:  AIDS Care       Date:  2000-08

3.  Unsafe injection practices in a cohort of injection drug users in Vancouver: could safer injecting rooms help?

Authors:  E Wood; M W Tyndall; P M Spittal; K Li; T Kerr; R S Hogg; J S Montaner; M V O'Shaughnessy; M T Schechter
Journal:  CMAJ       Date:  2001-08-21       Impact factor: 8.262

4.  Sexual transmission of HIV-1 among injection drug users in San Francisco, USA: risk-factor analysis.

Authors:  A H Kral; R N Bluthenthal; J Lorvick; L Gee; P Bacchetti; B R Edlin
Journal:  Lancet       Date:  2001-05-05       Impact factor: 79.321

5.  Sex-specific determinants of HIV infection among injection drug users in Montreal.

Authors:  J Bruneau; F Lamothe; J Soto; N Lachance; J Vincelette; A Vassal; E L Franco
Journal:  CMAJ       Date:  2001-03-20       Impact factor: 8.262

6.  Sex differences in risk factors for hiv seroconversion among injection drug users: a 10-year perspective.

Authors:  S A Strathdee; N Galai; M Safaiean; D D Celentano; D Vlahov; L Johnson; K E Nelson
Journal:  Arch Intern Med       Date:  2001-05-28

7.  Antiretroviral medication use among injection drug users: two potential futures.

Authors:  E Wood; M T Schechter; M W Tyndall; J S Montaner; M V O'Shaughnessy; R S Hogg
Journal:  AIDS       Date:  2000-06-16       Impact factor: 4.177

8.  Women, drugs and HIV/AIDS: results of a multicentre European study.

Authors:  P E Estebanez; N K Russell; M D Aguilar; F Béland; M V Zunzunegui
Journal:  Int J Epidemiol       Date:  2000-08       Impact factor: 7.196

9.  Hospital utilization and costs in a cohort of injection drug users.

Authors:  A Palepu; M W Tyndall; H Leon; J Muller; M V O'Shaughnessy; M T Schechter; A H Anis
Journal:  CMAJ       Date:  2001-08-21       Impact factor: 8.262

10.  Impact of HIV infection on mortality in a cohort of injection drug users.

Authors:  M W Tyndall; K J Craib; S Currie; K Li; M V O'Shaughnessy; M T Schechter
Journal:  J Acquir Immune Defic Syndr       Date:  2001-12-01       Impact factor: 3.731

View more
  87 in total

1.  HIV incidence among injection drug users in Vancouver.

Authors:  Robert S Remis
Journal:  CMAJ       Date:  2002-04-02       Impact factor: 8.262

2.  The cost-effectiveness of a modestly effective HIV vaccine in the United States.

Authors:  Elisa F Long; Douglas K Owens
Journal:  Vaccine       Date:  2011-04-19       Impact factor: 3.641

3.  Vide VIDUS.

Authors:  Ned Glick
Journal:  CMAJ       Date:  2003-08-05       Impact factor: 8.262

Review 4.  Deadly public policy: what the future could hold for the HIV epidemic among injection drug users in Vancouver.

Authors:  Michael V O'Shaughnessy; Robert S Hogg; Steffanie A Strathdee; Julio S G Montaner
Journal:  Curr HIV/AIDS Rep       Date:  2012-12       Impact factor: 5.071

5.  Service uptake and characteristics of injection drug users utilizing North America's first medically supervised safer injecting facility.

Authors:  Evan Wood; Mark W Tyndall; Zhenguo Qui; Ruth Zhang; Julio S G Montaner; Thomas Kerr
Journal:  Am J Public Health       Date:  2006-03-29       Impact factor: 9.308

6.  Adherence and plasma HIV RNA responses to highly active antiretroviral therapy among HIV-1 infected injection drug users.

Authors:  Evan Wood; Julio S G Montaner; Benita Yip; Mark W Tyndall; Martin T Schechter; Michael V O'Shaughnessy; Robert S Hogg
Journal:  CMAJ       Date:  2003-09-30       Impact factor: 8.262

7.  Factors associated with sex trade involvement among male participants in a prospective study of injection drug users.

Authors:  L M Kuyper; T M Lampinen; K Li; P M Spittal; R S Hogg; M T Schechter; E Wood
Journal:  Sex Transm Infect       Date:  2004-12       Impact factor: 3.519

8.  Impact of supply-side policies for control of illicit drugs in the face of the AIDS and overdose epidemics: investigation of a massive heroin seizure.

Authors:  Evan Wood; Mark W Tyndall; Patricia M Spittal; Kathy Li; Aslam H Anis; Robert S Hogg; Julio S G Montaner; Michael V O'Shaughnessy; Martin T Schechter
Journal:  CMAJ       Date:  2003-01-21       Impact factor: 8.262

9.  The Cedar Project: historical trauma, sexual abuse and HIV risk among young Aboriginal people who use injection and non-injection drugs in two Canadian cities.

Authors:  Margo E Pearce; Wayne M Christian; Katharina Patterson; Kat Norris; Akm Moniruzzaman; Kevin J P Craib; Martin T Schechter; Patricia M Spittal
Journal:  Soc Sci Med       Date:  2008-06       Impact factor: 4.634

10.  Potential use of safer injecting facilities among injection drug users in Vancouver's Downtown Eastside.

Authors:  Thomas Kerr; Evan Wood; Dan Small; Anita Palepu; Mark W Tyndall
Journal:  CMAJ       Date:  2003-10-14       Impact factor: 8.262

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.